Published in Vaccine Weekly, March 23rd, 2005
EntreMed scientists presented posters on three of its oncology programs including:
1) Panzem NCD (2-methoxyestradiol or 2ME2), the company's lead product candidate, which is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.